Rizatriptan: Difference between revisions

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Next edit →
VisualWikitext
imported>GreenC bot
 
imported>DocWatson42
Performed minor cleanup and wikification.
Line 1: Line 1:
{{Short description|Medication used for the treatment of migraine headaches}}
{{Short description|Medication used for the treatment of migraine headaches}}
{{Use dmy dates|date=December 2023}}
{{Use dmy dates|date=December 2023}}
{{cs1 config |name-list-style=vanc |display-authors=6}}
{{Cs1 config |name-list-style=vanc |display-authors=6}}
{{Drugbox
{{Drugbox
| Verifiedfields    = changed
| Verifiedfields    = changed
Line 90: Line 90:


<!-- Society and culture -->
<!-- Society and culture -->
Rizatriptan was patented in 1991 and came into medical use in 1998.<ref>{{cite web | title=Drug Approval Package: Maxalt/Rizatritan Benzoate NDA# 20864 & 20865 | website=U.S. [[Food and Drug Administration]] (FDA) | date=30 March 2001 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20864-20865.cfm | access-date=25 December 2023 | archive-date=6 December 2022 | archive-url=https://web.archive.org/web/20221206085052/https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20864-20865.cfm | url-status=dead }}</ref><ref name=Fis2006>{{cite book | vauthors = Fischer J, Ganellin CR |title= Analogue-based Drug Discovery |date=2006 |publisher=John Wiley & Sons |isbn=9783527607495 |page=531 |url=https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA531 }}</ref> It is available as a [[generic medication]].<ref name=BNF76>{{cite book|title=British National Formulary : BNF 76|date=2018|publisher=Pharmaceutical Press|isbn=9780857113382|pages=473|edition=76}}</ref> In 2022, it was the 190th most commonly prescribed medication in the United States, with more than 2{{nbsp}}million prescriptions.<ref>{{cite web | title=The Top 300 of 2022 | url=https://clincalc.com/DrugStats/Top300Drugs.aspx | website=ClinCalc | access-date=30 August 2024 | archive-date=30 August 2024 | archive-url=https://web.archive.org/web/20240830202410/https://clincalc.com/DrugStats/Top300Drugs.aspx | url-status=live }}</ref><ref>{{cite web | title = Rizatriptan Drug Usage Statistics, United States, 2013 - 2022 | website = ClinCalc | url = https://clincalc.com/DrugStats/Drugs/Rizatriptan | access-date = 30 August 2024 }}</ref> Rizatriptan is available in combination with meloxicam as [[meloxicam/rizatriptan]].
Rizatriptan was patented in 1991 and came into medical use in 1998.<ref>{{cite web |title=Drug Approval Package: Maxalt/Rizatritan Benzoate NDA# 20864 & 20865 |publisher=U.S. [[Food and Drug Administration]] (FDA) |date=30 March 2001 |url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20864-20865.cfm |access-date=25 December 2023 |archive-date=6 December 2022 |archive-url=https://web.archive.org/web/20221206085052/https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20864-20865.cfm |url-status=dead }}</ref><ref name=Fis2006>{{cite book | vauthors = Fischer J, Ganellin CR |title= Analogue-based Drug Discovery |date=2006 |publisher=John Wiley & Sons |isbn=9783527607495 |page=531 |url=https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA531 }}</ref> It is available as a [[generic medication]].<ref name=BNF76>{{cite book|title=British National Formulary: BNF 76|date=2018|publisher=Pharmaceutical Press|isbn=9780857113382|pages=473|edition=76}}</ref> In 2022, it was the 190th most commonly prescribed medication in the United States, with more than two million prescriptions.<ref>{{cite web | title=The Top 300 of 2022 | url=https://clincalc.com/DrugStats/Top300Drugs.aspx | website=ClinCalc | access-date=30 August 2024 | archive-date=30 August 2024 | archive-url=https://web.archive.org/web/20240830202410/https://clincalc.com/DrugStats/Top300Drugs.aspx | url-status=live }}</ref><ref>{{cite web | title = Rizatriptan Drug Usage Statistics, United States, 2013 - 2022 | website = ClinCalc | url = https://clincalc.com/DrugStats/Drugs/Rizatriptan | access-date = 30 August 2024 }}</ref> Rizatriptan is available in combination with [[meloxicam]] as [[meloxicam/rizatriptan]].


==Medical uses==
==Medical uses==

Revision as of 12:10, 3 June 2025

Template:Short description Template:Use dmy dates Template:Cs1 config Template:Drugbox

Rizatriptan, sold under the brand name Maxalt among others, is a medication used for the treatment of migraine headaches.[1][2] It is taken by mouth.[1][2] It can also be applied on the tongue.[3] It is a serotonin (5-HT) 1B/1D receptor agonist (triptan).[1][3]

Common side effects include chest pain, dizziness, dry mouth, and tingling.[2] Other side effects may include myocardial infarction, stroke, high blood pressure, serotonin syndrome, and anaphylaxis.[2] Excessive use may result in medication overuse headaches.[2] Use is not recommended during pregnancy and breastfeeding is not recommended within 24 hours after taking a dose.[4] Rizatriptan is in the triptan class and is believed to work by activating the 5-HT1 receptor.[2]

Rizatriptan was patented in 1991 and came into medical use in 1998.[5][6] It is available as a generic medication.[4] In 2022, it was the 190th most commonly prescribed medication in the United States, with more than two million prescriptions.[7][8] Rizatriptan is available in combination with meloxicam as meloxicam/rizatriptan.

Medical uses

Rizatriptan is indicated to treat acute migraine attacks with or without aura.[1][3] It does not prevent future migraine attacks.[9] A 2010 review found rizatriptan to be more efficacious and tolerable than sumatriptan.[10]

Contraindications

Rizatriptan and other triptans can cause vasoconstriction, they are contraindicated in people with cardiovascular conditions.[11]

Adverse effects

Frequent adverse effects (incidence less than 10%) are dizziness, drowsiness, asthenia/fatigue, and nausea. Clinical adverse experiences were typically mild and short-lasting (2–3 hours).[11]

Interactions

Mechanism of action

Script error: No such module "labelled list hatnote". Rizatriptan acts as an agonist at serotonin 5-HT1B and 5-HT1D receptors.[13] Like the other triptans sumatriptan and zolmitriptan, rizatriptan induces vasoconstriction—possibly by inhibiting the release of calcitonin gene-related peptide from sensory neurons in the trigeminal nerve.[13]

Society and culture

Brand names

Brand names include Rizalt, Rizalt RPD, Rizact (India), Rizafilm,[3] Maxalt,[1] and Maxalt-MLT.[1][14][15][16]

References

Template:Reflist

Template:Triptans Template:Serotonergics Script error: No such module "Navbox". Script error: No such module "Navbox". Template:Portal bar Template:Authority control

  1. ↑ a b c d e f Cite error: Invalid <ref> tag; no text was provided for refs named Maxalt FDA label
  2. ↑ a b c d e f Script error: No such module "citation/CS1".
  3. ↑ a b c d Cite error: Invalid <ref> tag; no text was provided for refs named Rizafilm FDA label
  4. ↑ a b Script error: No such module "citation/CS1".
  5. ↑ Script error: No such module "citation/CS1".
  6. ↑ Script error: No such module "citation/CS1".
  7. ↑ Script error: No such module "citation/CS1".
  8. ↑ Script error: No such module "citation/CS1".
  9. ↑ Script error: No such module "citation/CS1".
  10. ↑ Script error: No such module "Citation/CS1".
  11. ↑ a b Script error: No such module "Citation/CS1".
  12. ↑ Script error: No such module "Citation/CS1".
  13. ↑ a b Script error: No such module "Citation/CS1".
  14. ↑ Script error: No such module "citation/CS1".
  15. ↑ Script error: No such module "citation/CS1".
  16. ↑ Script error: No such module "citation/CS1".
Retrieved from "http://debianws.lexgopc.com/wiki143/index.php?title=Rizatriptan&oldid=835522"